during the fast evolving field of oncology research, precise and economical mutation screening is critical for producing qualified therapies. The KRAS companies Platform plays a pivotal purpose With this landscape by offering thorough answers for KRAS mutation profiling and analysis. KRAS mutations, located in approximately ninety five% of RAS-simi